

Ajit P Limaye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4957588/publications.pdf>

Version: 2024-02-01

109
papers

6,424
citations

87723

38
h-index

66788

78
g-index

110
all docs

110
docs citations

110
times ranked

5986
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. <i>Transplantation</i> , 2005, 79, 1277-1286. | 0.5 | 842 |
| 2 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. <i>Lancet</i> , The, 2000, 356, 645-649. | 6.3 | 505 |
| 3 | Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 413. | 3.8 | 401 |
| 4 | Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4090-e4099. | 2.9 | 332 |
| 5 | Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. <i>Transplantation</i> , 2006, 81, 1645-1652. | 0.5 | 217 |
| 6 | High Incidence of Ganciclovir-Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. <i>Journal of Infectious Diseases</i> , 2002, 185, 20-27. | 1.9 | 216 |
| 7 | Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation. <i>Annals of Internal Medicine</i> , 2010, 152, 761. | 2.0 | 212 |
| 8 | Ganciclovir-Resistant Cytomegalovirus in Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2002, 35, 866-872. | 2.9 | 175 |
| 9 | Extended Valganciclovir Prophylaxis in D+/R ⁺ Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study. <i>Transplantation</i> , 2010, 90, 1427-1431. | 0.5 | 175 |
| 10 | Treatment of Refractory BK Virus-Associated Nephropathy With Cidofovir. <i>American Journal of Transplantation</i> , 2003, 3, 186-191. | 2.6 | 166 |
| 11 | Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis 1. <i>Transplantation</i> , 2004, 78, 1390-1396. | 0.5 | 141 |
| 12 | Transmission of <i>Histoplasma capsulatum</i> by Organ Transplantation. <i>New England Journal of Medicine</i> , 2000, 343, 1163-1166. | 13.9 | 139 |
| 13 | Marked Variability of BK Virus Load Measurement Using Quantitative Real-Time PCR among Commonly Used Assays. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2671-2680. | 1.8 | 138 |
| 14 | Polyomavirus Nephropathy in Pediatric Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 2109-2117. | 2.6 | 136 |
| 15 | Polyomavirus Nephropathy in Native Kidneys of Non-Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 614-620. | 2.6 | 112 |
| 16 | Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1113-1116. | 1.8 | 109 |
| 17 | Pseudomembranous Colitis Caused by a Toxin A ⁺ B ⁺ Strain of <i>Clostridium difficile</i> . <i>Journal of Clinical Microbiology</i> , 2000, 38, 1696-1697. | 1.8 | 104 |
| 18 | Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1378. | 3.8 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Treatment of Tularemia with Fluoroquinolones: Two Cases and Review. <i>Clinical Infectious Diseases</i> , 1999, 29, 922-924. | 2.9 | 98 |
| 20 | Incidence and Clinical Features of Ganciclovir- Resistant Cytomegalovirus Disease in Heart Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2007, 45, 439-447. | 2.9 | 96 |
| 21 | Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. <i>Clinical Infectious Diseases</i> , 2016, 62, 313-319. | 2.9 | 92 |
| 22 | Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 731. | 3.8 | 91 |
| 23 | Six Rapid Tests for Direct Detection of <i>Clostridium difficile</i> and Its Toxins in Fecal Samples Compared with the Fibroblast Cytotoxicity Assay. <i>Journal of Clinical Microbiology</i> , 2003, 41, 667-670. | 1.8 | 84 |
| 24 | A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2505-2516. | 2.6 | 84 |
| 25 | Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, S1-S17. | 0.3 | 83 |
| 26 | Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 1885-1890. | 2.6 | 82 |
| 27 | Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2017, 65, 57-63. | 2.9 | 81 |
| 28 | Cross-Reactivity of T Lymphocytes Recognizing a Human Cytotoxic T-Lymphocyte Epitope within BK and JC Virus VP1 Polypeptides. <i>Journal of Virology</i> , 2005, 79, 11170-11178. | 1.5 | 80 |
| 29 | CMV in critically ill patients: pathogen or bystander?. <i>Reviews in Medical Virology</i> , 2010, 20, 372-379. | 3.9 | 74 |
| 30 | Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no"? <i>American Journal of Transplantation</i> , 2020, 20, 1787-1794. | 2.6 | 74 |
| 31 | Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13622. | 0.8 | 71 |
| 32 | Programmed Death-1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 25-33. | 1.9 | 63 |
| 33 | COVID-19 "Lessons Learned and Questions Remaining. <i>Clinical Infectious Diseases</i> , 2021, 72, 2225-2240. | 2.9 | 54 |
| 34 | Statin Use and Bone Mineral Density in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1320-1321. | 2.6 | 53 |
| 35 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786. | 2.9 | 53 |
| 36 | Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. <i>Clinical Microbiology Reviews</i> , 2020, 34, . | 5.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Antiviral resistance in cytomegalovirus: An emerging problem in organ transplant recipients. <i>Seminars in Respiratory Infections</i> , 2002, 17, 265-273. | 1.3 | 44 |
| 38 | Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults*. <i>Critical Care Medicine</i> , 2015, 43, 1415-1422. | 0.4 | 39 |
| 39 | Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 617-628. | 2.5 | 39 |
| 40 | Outbreak of <i>Stenotrophomonas maltophilia</i> Bacteremia Among Patients Undergoing Bone Marrow Transplantation: Association With Faulty Replacement of Handwashing Soap. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 756-758. | 1.0 | 37 |
| 41 | BK virus-associated nephropathy in kidney transplant recipients. <i>Reviews in Medical Virology</i> , 2004, 14, 193-205. | 3.9 | 34 |
| 42 | Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13687. | 0.7 | 34 |
| 43 | Clinical Impact Associated with Corrected Results in Clinical Microbiology Testing. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2188-2193. | 1.8 | 30 |
| 44 | SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1021-1024. | 3.0 | 28 |
| 45 | Invasive Pneumococcal Infections in Adult Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 1366-1371. | 2.6 | 27 |
| 46 | Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis. <i>Journal of Infectious Diseases</i> , 2019, 220, 752-760. | 1.9 | 27 |
| 47 | Changing the paradigm of organ utilization from <sc>PHS</sc> increased risk donors: an opportunity whose time has come?. <i>Clinical Transplantation</i> , 2015, 29, 724-727. | 0.8 | 24 |
| 48 | Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1210-1219. | 0.3 | 24 |
| 49 | Detection of SARS-CoV-2 by bronchoscopy after negative nasopharyngeal testing: Stay vigilant for COVID-19. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101120. | 0.2 | 24 |
| 50 | Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. <i>Transplant International</i> , 2011, 24, 920-931. | 0.8 | 22 |
| 51 | Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2019, 221, 379-388. | 1.9 | 22 |
| 52 | Reported β -Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 1587-1594. | 2.9 | 22 |
| 53 | Infection control strategies that successfully controlled an outbreak of <i>Mycobacterium abscessus</i> at a cystic fibrosis center. <i>American Journal of Infection Control</i> , 2016, 44, 154-159. | 1.1 | 21 |
| 54 | Current Understanding of Cytomegalovirus Reactivation in Critical Illness. <i>Journal of Infectious Diseases</i> , 2020, 221, S94-S102. | 1.9 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Emerging evidence to support not always "just saying no" to SARS-CoV-2 positive donors. American Journal of Transplantation, 2020, 20, 3261-3262. | 2.6 | 20 |
| 56 | Rapid Detection of Human Cytomegalovirus UL97 and UL54 Mutations Directly from Patient Samples. Journal of Clinical Microbiology, 2013, 51, 2354-2359. | 1.8 | 18 |
| 57 | Infections in Solid-Organ Transplant Recipients. , 2015, , 3440-3452. | | 18 |
| 58 | Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. Clinical Transplantation, 2018, 32, e13370. | 0.8 | 16 |
| 59 | Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. Clinical Infectious Diseases, 2021, 73, e2739-e2745. | 2.9 | 15 |
| 60 | Expedited SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation. American Journal of Transplantation, 2020, 20, 3106-3112. | 2.6 | 13 |
| 61 | Quantitation of Cytomegalovirus DNA Load in Dried Blood Spots Correlates Well with Plasma Viral Load. Journal of Clinical Microbiology, 2013, 51, 2360-2364. | 1.8 | 12 |
| 62 | Respiratory virus infections and chronic lung allograft dysfunction: Assessment of virology determinants. Journal of Heart and Lung Transplantation, 2016, 35, 946-947. | 0.3 | 12 |
| 63 | Expanding access to transplantation with hepatitis C-positive donors: A new perspective on an old issue. Clinical Transplantation, 2017, 31, e12884. | 0.8 | 11 |
| 64 | Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transplant Infectious Disease, 2018, 20, e12928. | 0.7 | 11 |
| 65 | Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. Journal of Infectious Diseases, 2021, 223, 2108-2112. | 1.9 | 11 |
| 66 | Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation, 2016, 100, 210-216. | 0.5 | 10 |
| 67 | Cytomegalovirus immunoglobulin G titers do not predict reactivation risk in immunocompetent hosts. Journal of Medical Virology, 2019, 91, 836-844. | 2.5 | 10 |
| 68 | Listing practices and graft utilization of hepatitis C-positive deceased donors in liver and kidney transplant. Surgery, 2019, 166, 102-108. | 1.0 | 9 |
| 69 | Transplant tourism complicated by life-threatening New Delhi metallo-beta-lactamase-1 infection. American Journal of Transplantation, 2019, 19, 1224-1228. | 2.6 | 9 |
| 70 | Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients. Transplant Infectious Disease, 2020, 22, e13255. | 0.7 | 9 |
| 71 | Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Transplantation, 2018, 102, 632-639. | 0.5 | 8 |
| 72 | Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transplantation, 2021, 27, 1302-1311. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Is Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?. <i>Annals of Transplantation</i> , 2017, 22, 663-664. | 0.5 | 8 |
| 74 | Willingness to Consider Increased-Risk Donors: A Single-Center Experience in Kidney Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 387-392. | 0.5 | 8 |
| 75 | A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. <i>Journal of Clinical Virology</i> , 2015, 62, 98-102. | 1.6 | 7 |
| 76 | Prediction of Infection After Solid Organ Transplantation: Is Measuring Cell-Mediated Immunity the Answer?. <i>Clinical Infectious Diseases</i> , 2018, 66, 1398-1399. | 2.9 | 7 |
| 77 | Xanthogranulomatous Pyelonephritis With Direct Extension Into the Liver. <i>American Journal of Medicine</i> , 2020, 133, 1054-1055. | 0.6 | 6 |
| 78 | Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 436-442. | 1.9 | 6 |
| 79 | Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19. <i>Gastroenterology</i> , 2021, 160, 1012-1013. | 0.6 | 6 |
| 80 | Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718. | 2.9 | 6 |
| 81 | LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+Râ”) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S766-S766. | 0.4 | 5 |
| 82 | Trillions and Trillions: Herpes Simplex Virusâ€”1 Hepatitis in an Immunocompetent Adult. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz465. | 0.4 | 4 |
| 83 | Variability in assessing for BK viremia: whole blood is not reliable and plasma is not above reproach - a retrospective analysis. <i>Transplant International</i> , 2017, 30, 670-678. | 0.8 | 3 |
| 84 | Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 1073-1077. | 1.9 | 3 |
| 85 | Disseminated <i>Mycobacterium haemophilum</i> With Tenosynovitis in a Liver Transplant Recipient. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e36-e37. | 0.5 | 3 |
| 86 | Systematic Assessment of Culture Review as a Tool to Assess Errors in the Clinical Microbiology Laboratory. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1792-1795. | 1.2 | 3 |
| 87 | Reply to Munoz and Santin. <i>Clinical Infectious Diseases</i> , 2014, 58, 905-906. | 2.9 | 2 |
| 88 | Comparison of self-collected nasal swabs with oral washes for sequential viral load monitoring in lung transplant recipients with respiratory virus infection. <i>Journal of Clinical Virology</i> , 2017, 91, 49-51. | 1.6 | 2 |
| 89 | Immunosuppression in solid organ transplant recipients with Covidâ€”19: More data, but still complicated. <i>Transplant Infectious Disease</i> , 2021, 23, e13650. | 0.7 | 2 |
| 90 | Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Direct Detection of Legionellae in Respiratory Tract Specimens by Using Fluorescence In Situ Hybridization. , 0, , 221-224. | | 2 |
| 92 | Changing landscape of hepatitis C virus-positive donors. World Journal of Hepatology, 2017, 9, 905. | 0.8 | 2 |
| 93 | Reply to Hage and Schuurmans. Clinical Infectious Diseases, 2021, 73, e2833-e2834. | 2.9 | 2 |
| 94 | Apples to Apples: The Challenges of Studying COVID-19 Mortality in Solid Organ Transplant Recipients. American Journal of Transplantation, 2022, , . | 2.6 | 2 |
| 95 | Misplaced emphasis, misunderstood risk: a cultural history of Public Health Service infectious disease guidelines. Current Opinion in Organ Transplantation, 2022, 27, 159-164. | 0.8 | 2 |
| 96 | Vaccination, Transplantation, and a Social Contract. Journal of the American Society of Nephrology: JASN, 2022, 33, 1445-1447. | 3.0 | 2 |
| 97 | Time to Antibiotics in Solid Organ Transplant Recipients With Gram-Negative Rod Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 1868-1869. | 2.9 | 1 |
| 98 | A Prospective Study Comparing Self-Collected Nasal Swabs to Oral Washes for Monitoring Viral Load Kinetics in Lung Transplant Recipients With Respiratory Virus Infection. Open Forum Infectious Diseases, 2016, 3, . | 0.4 | 1 |
| 99 | NAT testing in recipients of hepatitis C aviremic donor organs. American Journal of Transplantation, 2018, 18, 1030. | 2.6 | 1 |
| 100 | Hepatitis C NAT status in the UNOS database. American Journal of Transplantation, 2019, 19, 1870. | 2.6 | 1 |
| 101 | Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. Transplant Infectious Disease, 2021, 23, e13581. | 0.7 | 1 |
| 102 | 1225Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically Ill Immunocompetent Adults. Open Forum Infectious Diseases, 2014, 1, S43-S43. | 0.4 | 0 |
| 103 | Letter to the Editor. Clinical Infectious Diseases, 2020, 70, 719. | 2.9 | 0 |
| 104 | In with the new and, mostly better: Considering the OPTN blood-borne virus policy updates. American Journal of Transplantation, 2021, 21, 3494-3495. | 2.6 | 0 |
| 105 | Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.. Blood, 2006, 108, 2936-2936. | 0.6 | 0 |
| 106 | Human Polyomaviruses. , 2008, , 1058-1062. | | 0 |
| 107 | A Dark Horse Diagnosis. Journal of Hospital Medicine, 2018, 13, 790-794. | 0.7 | 0 |
| 108 | Multiple liver lesions in a lung transplant recipient. American Journal of Transplantation, 2021, 21, 3801-3803. | 2.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. <i>Transplantation Direct</i> , 2021, 7, e637. | 0.8 | 0 |